Efgartigimod then Telitacicept for Myasthenia Gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests whether taking two drugs one after the other—efgartigimod followed by telitacicept—is safe and effective for people with generalized myasthenia gravis. It may offer a new treatment option if standard therapy isn't enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have been diagnosed with generalized myasthenia gravis and tested positive for acetylcholine receptor antibodies (AChR-Ab).
- Your symptoms are moderate to severe, such as having a score of at least 6 on the MG-ADL scale or at least 8 on the QMG scale.
- You have not used certain biologic drugs recently, like Telitacicept within the past 2 months, Efgartigimod within 1 month, or Rituximab within 6 months.
- You do not have active infections (like tuberculosis or hepatitis), serious liver or kidney problems, or other active autoimmune diseases.
- You are not pregnant or breastfeeding, and you can avoid live vaccines during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called telitacicept combined with low-dose steroids for people with hard-to-treat myasthenia gravis. The goal is to see if this combination can better control symptoms that haven't improved with standard treatments.
This trial tests whether a follow-up treatment with ublituximab (given as an infusion) can help myasthenia gravis patients who first received efgartigimod. The goal is to see if it provides lasting control of MG symptoms.
This trial tests if a drug called efgartigimod can help people with generalized myasthenia gravis who have recently had a severe flare-up. Participants will get the drug as maintenance therapy to prevent future crises.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This trial tests whether nipocalimab works better than efgartigimod for people with generalized myasthenia gravis (gMG). If you have gMG with certain antibodies and current treatments aren't working well enough, this study may help find a better option.
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.